174 related articles for article (PubMed ID: 30468899)
1. Pirfenidone-induced photosensitivity confirmed by pathological phototest.
Ferrer Guillén B; Giácaman MM; Valenzuela Oñate C; Magdaleno Tapial J; Hernández Bel P; Pérez Ferriols A
Photodiagnosis Photodyn Ther; 2019 Mar; 25():103-105. PubMed ID: 30468899
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of skin photosensitivity induced by pirfenidone.
Wang C; He Y; Sun W; Wu C; Li Z; Sun L
J Clin Pharm Ther; 2022 Feb; 47(2):194-199. PubMed ID: 34655088
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Xaubet A; Serrano-Mollar A; Ancochea J
Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis.
Papakonstantinou E; Prasse A; Schacht V; Kapp A; Raap U
J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1354-6. PubMed ID: 27005406
[TBL] [Abstract][Full Text] [Related]
5. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.
Ogura T; Azuma A; Inoue Y; Taniguchi H; Chida K; Bando M; Niimi Y; Kakutani S; Suga M; Sugiyama Y; Kudoh S; Nukiwa T
Respir Investig; 2015 Sep; 53(5):232-41. PubMed ID: 26344613
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M
Respiration; 2014; 88(3):199-207. PubMed ID: 25115833
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.
Cottin V; Maher T
Eur Respir Rev; 2015 Mar; 24(135):58-64. PubMed ID: 25726556
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone in idiopathic pulmonary fibrosis.
Maher TM
Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.
Kim ES; Keating GM
Drugs; 2015 Feb; 75(2):219-30. PubMed ID: 25604027
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].
Tokura T; Oku H; Tsukamoto Y
Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):97-104. PubMed ID: 19672005
[No Abstract] [Full Text] [Related]
13. Pirfenidone-induced photoleukomelanoderma in a patient with idiopathic pulmonary fibrosis.
Tsuruta A; Washio K; Fukunaga A; Nishigori C
J Dermatol; 2016 Feb; 43(2):207-9. PubMed ID: 26119131
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
[TBL] [Abstract][Full Text] [Related]
15. Perils with Pirfenidone and "the tuberculosis link".
Hande MH; Acharya KV; Shreenivasa A; Nayak K; Arun S
Int J Mycobacteriol; 2019; 8(3):298-301. PubMed ID: 31512609
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
Azuma A
Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
[TBL] [Abstract][Full Text] [Related]
18. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
Selvaggio AS; Noble PW
Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
[TBL] [Abstract][Full Text] [Related]
20. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Anderson A; Shifren A; Nathan SD
Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
